The Effect Of Fluvoxamine On Sleep Architecture Of Depressed Patients With Insomnia: An 8-Week, Open-Label, Baseline-Controlled Study
Yanli Hao,1 Yuanyuan Hu,2 Haili Wang,3 Dhirendra Paudel,4,5 Yan Xu,4–6 Bin Zhang4–6 1Department of Human Anatomy, Guangzhou Medical University, Guangzhou 511436, People’s Republic of China; 2Zhongshan Third People’s Hospital, Zhongshan, People’s Repu...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2019
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/79de632591874a0aafb1dc664777217f |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:79de632591874a0aafb1dc664777217f |
|---|---|
| record_format |
dspace |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
fluvoxamine depression insomnia polysomnogram Psychiatry RC435-571 Neurophysiology and neuropsychology QP351-495 |
| spellingShingle |
fluvoxamine depression insomnia polysomnogram Psychiatry RC435-571 Neurophysiology and neuropsychology QP351-495 Hao Y Hu Y Wang H Paudel D Xu Y Zhang B The Effect Of Fluvoxamine On Sleep Architecture Of Depressed Patients With Insomnia: An 8-Week, Open-Label, Baseline-Controlled Study |
| description |
Yanli Hao,1 Yuanyuan Hu,2 Haili Wang,3 Dhirendra Paudel,4,5 Yan Xu,4–6 Bin Zhang4–6 1Department of Human Anatomy, Guangzhou Medical University, Guangzhou 511436, People’s Republic of China; 2Zhongshan Third People’s Hospital, Zhongshan, People’s Republic of China; 3Ganzhou Third People’s Hospital, Ganzhou, People’s Republic of China; 4Department of Psychiatry, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China; 5Guangdong-Hong Kong-Macao Greater Bay Area Center for Brain Science and Brain-Inspired Intelligence, Guangzhou, People’s Republic of China; 6Guangdong Provincial Mental Health Institute, Guangzhou, People’s Republic of ChinaCorrespondence: Bin ZhangDepartment of Psychiatry, Nanfang Hospital, Southern Medical University, No 1838, Guangzhou Northern Road, Guangzhou 510515, People’s Republic of ChinaTel/fax +8620-62786731Email zhang73bin@hotmail.comBackground and aims: Fluvoxamine can markedly increase the serum melatonin level, which regulates human circadian rhythm. However, only limited research has evaluated the effects of fluvoxamine on sleep architecture. Thus, the current study aims to investigate the effect of fluvoxamine on PSG characteristics and the impact of persistent insomnia on the prognosis of depression in the depressed individual with insomnia over the course of 8 weeks.Methods: Thirty-one clinically depressed patients with insomnia were enrolled in this 8-week, open-label, baseline-controlled study, and 23 patients completed the study. All participants were assigned to receive fluvoxamine for 8 weeks. They were assessed by the PSG, Hamilton Rating Scale for Depression (17 items) (HRSD-17), Clinical Global Index, Pittsburgh Sleep Quality Index, and Epworth Sleepiness Scale at baseline and the following visits, which were at day 14, day 28, and day 56. A patient with an ≥4 HRSD-17 sleep disturbance factor score at both baseline and endpoint (day 56) was defined as a patient with persistent insomnia.Results: Compared with baseline, the percentage of stage 3 sleep had significantly (F=11.630, P=0.001) increased in all 3 visits. Moreover, the percentage of rapid eye movement sleep was reduced during the study, with only a significant difference (F=3.991, P=0.027) between baseline and day 14. Finally, 47.8% (11/23) of the participants were in remission, and 60.9% (14/23) of them did not report insomnia. The clinical remission ratio of the persistent insomnia group (11.1% [1/9]) (χ2=8.811, P=0.004) was significantly lower than that of the non-insomnia group (71.4% [10/14]) at the endpoint. Additionally, during the first clinical evaluation (day 14), patients without insomnia had significantly higher final remission ratios than patients with insomnia (80% [8/10] versus 30.8% [4/13]; χ2=5.79; P=0.016).Conclusion: Fluvoxamine improved PSG parameters and ameliorated complaints of insomnia simultaneously during this 8-week study. Moreover, depressed individuals who reported persistent insomnia were at higher risk of remaining depressed by the end of the trial, which might be forecasted by the sleep status on day 14.Trial registration: The Effect of Fluvoxamine on Polysomnogram in Depressed Patients with Insomnia; https://clinicaltrials.gov/ct2/show/NCT02442713. Registry identifier: NCT02442713. Registry date: May 13, 2015.Keywords: fluvoxamine, depression, insomnia, polysomnogram |
| format |
article |
| author |
Hao Y Hu Y Wang H Paudel D Xu Y Zhang B |
| author_facet |
Hao Y Hu Y Wang H Paudel D Xu Y Zhang B |
| author_sort |
Hao Y |
| title |
The Effect Of Fluvoxamine On Sleep Architecture Of Depressed Patients With Insomnia: An 8-Week, Open-Label, Baseline-Controlled Study |
| title_short |
The Effect Of Fluvoxamine On Sleep Architecture Of Depressed Patients With Insomnia: An 8-Week, Open-Label, Baseline-Controlled Study |
| title_full |
The Effect Of Fluvoxamine On Sleep Architecture Of Depressed Patients With Insomnia: An 8-Week, Open-Label, Baseline-Controlled Study |
| title_fullStr |
The Effect Of Fluvoxamine On Sleep Architecture Of Depressed Patients With Insomnia: An 8-Week, Open-Label, Baseline-Controlled Study |
| title_full_unstemmed |
The Effect Of Fluvoxamine On Sleep Architecture Of Depressed Patients With Insomnia: An 8-Week, Open-Label, Baseline-Controlled Study |
| title_sort |
effect of fluvoxamine on sleep architecture of depressed patients with insomnia: an 8-week, open-label, baseline-controlled study |
| publisher |
Dove Medical Press |
| publishDate |
2019 |
| url |
https://doaj.org/article/79de632591874a0aafb1dc664777217f |
| work_keys_str_mv |
AT haoy theeffectoffluvoxamineonsleeparchitectureofdepressedpatientswithinsomniaan8weekopenlabelbaselinecontrolledstudy AT huy theeffectoffluvoxamineonsleeparchitectureofdepressedpatientswithinsomniaan8weekopenlabelbaselinecontrolledstudy AT wangh theeffectoffluvoxamineonsleeparchitectureofdepressedpatientswithinsomniaan8weekopenlabelbaselinecontrolledstudy AT paudeld theeffectoffluvoxamineonsleeparchitectureofdepressedpatientswithinsomniaan8weekopenlabelbaselinecontrolledstudy AT xuy theeffectoffluvoxamineonsleeparchitectureofdepressedpatientswithinsomniaan8weekopenlabelbaselinecontrolledstudy AT zhangb theeffectoffluvoxamineonsleeparchitectureofdepressedpatientswithinsomniaan8weekopenlabelbaselinecontrolledstudy AT haoy effectoffluvoxamineonsleeparchitectureofdepressedpatientswithinsomniaan8weekopenlabelbaselinecontrolledstudy AT huy effectoffluvoxamineonsleeparchitectureofdepressedpatientswithinsomniaan8weekopenlabelbaselinecontrolledstudy AT wangh effectoffluvoxamineonsleeparchitectureofdepressedpatientswithinsomniaan8weekopenlabelbaselinecontrolledstudy AT paudeld effectoffluvoxamineonsleeparchitectureofdepressedpatientswithinsomniaan8weekopenlabelbaselinecontrolledstudy AT xuy effectoffluvoxamineonsleeparchitectureofdepressedpatientswithinsomniaan8weekopenlabelbaselinecontrolledstudy AT zhangb effectoffluvoxamineonsleeparchitectureofdepressedpatientswithinsomniaan8weekopenlabelbaselinecontrolledstudy |
| _version_ |
1718399819075026944 |
| spelling |
oai:doaj.org-article:79de632591874a0aafb1dc664777217f2021-12-02T06:36:47ZThe Effect Of Fluvoxamine On Sleep Architecture Of Depressed Patients With Insomnia: An 8-Week, Open-Label, Baseline-Controlled Study1179-1608https://doaj.org/article/79de632591874a0aafb1dc664777217f2019-11-01T00:00:00Zhttps://www.dovepress.com/the-effect-of-fluvoxamine-on-sleep-architecture-of-depressed-patients--peer-reviewed-article-NSShttps://doaj.org/toc/1179-1608Yanli Hao,1 Yuanyuan Hu,2 Haili Wang,3 Dhirendra Paudel,4,5 Yan Xu,4–6 Bin Zhang4–6 1Department of Human Anatomy, Guangzhou Medical University, Guangzhou 511436, People’s Republic of China; 2Zhongshan Third People’s Hospital, Zhongshan, People’s Republic of China; 3Ganzhou Third People’s Hospital, Ganzhou, People’s Republic of China; 4Department of Psychiatry, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China; 5Guangdong-Hong Kong-Macao Greater Bay Area Center for Brain Science and Brain-Inspired Intelligence, Guangzhou, People’s Republic of China; 6Guangdong Provincial Mental Health Institute, Guangzhou, People’s Republic of ChinaCorrespondence: Bin ZhangDepartment of Psychiatry, Nanfang Hospital, Southern Medical University, No 1838, Guangzhou Northern Road, Guangzhou 510515, People’s Republic of ChinaTel/fax +8620-62786731Email zhang73bin@hotmail.comBackground and aims: Fluvoxamine can markedly increase the serum melatonin level, which regulates human circadian rhythm. However, only limited research has evaluated the effects of fluvoxamine on sleep architecture. Thus, the current study aims to investigate the effect of fluvoxamine on PSG characteristics and the impact of persistent insomnia on the prognosis of depression in the depressed individual with insomnia over the course of 8 weeks.Methods: Thirty-one clinically depressed patients with insomnia were enrolled in this 8-week, open-label, baseline-controlled study, and 23 patients completed the study. All participants were assigned to receive fluvoxamine for 8 weeks. They were assessed by the PSG, Hamilton Rating Scale for Depression (17 items) (HRSD-17), Clinical Global Index, Pittsburgh Sleep Quality Index, and Epworth Sleepiness Scale at baseline and the following visits, which were at day 14, day 28, and day 56. A patient with an ≥4 HRSD-17 sleep disturbance factor score at both baseline and endpoint (day 56) was defined as a patient with persistent insomnia.Results: Compared with baseline, the percentage of stage 3 sleep had significantly (F=11.630, P=0.001) increased in all 3 visits. Moreover, the percentage of rapid eye movement sleep was reduced during the study, with only a significant difference (F=3.991, P=0.027) between baseline and day 14. Finally, 47.8% (11/23) of the participants were in remission, and 60.9% (14/23) of them did not report insomnia. The clinical remission ratio of the persistent insomnia group (11.1% [1/9]) (χ2=8.811, P=0.004) was significantly lower than that of the non-insomnia group (71.4% [10/14]) at the endpoint. Additionally, during the first clinical evaluation (day 14), patients without insomnia had significantly higher final remission ratios than patients with insomnia (80% [8/10] versus 30.8% [4/13]; χ2=5.79; P=0.016).Conclusion: Fluvoxamine improved PSG parameters and ameliorated complaints of insomnia simultaneously during this 8-week study. Moreover, depressed individuals who reported persistent insomnia were at higher risk of remaining depressed by the end of the trial, which might be forecasted by the sleep status on day 14.Trial registration: The Effect of Fluvoxamine on Polysomnogram in Depressed Patients with Insomnia; https://clinicaltrials.gov/ct2/show/NCT02442713. Registry identifier: NCT02442713. Registry date: May 13, 2015.Keywords: fluvoxamine, depression, insomnia, polysomnogramHao YHu YWang HPaudel DXu YZhang BDove Medical PressarticlefluvoxaminedepressioninsomniapolysomnogramPsychiatryRC435-571Neurophysiology and neuropsychologyQP351-495ENNature and Science of Sleep, Vol Volume 11, Pp 291-300 (2019) |